CRL vs INCY: stock comparison and AI forecast
Charles River Laboratories International, Inc. (CRL) and Incyte Corp (INCY) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CRL Charles River Laboratories International, Inc.
- Market Cap
- $16.80B
- P/E Ratio
- –
- Size
- large-cap
- AI Forecast
INCY Incyte Corp
- Market Cap
- $23.57B
- P/E Ratio
- 44.8x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- INCY is 1.4 times larger than CRL by market capitalization ($23.57B against $16.80B).
- INCY turns 6.7% of its revenue into net income, against -6.0% for CRL.
- CRL carries 1.64 times debt per unit of equity, against 0.29 times for INCY.
- Both companies share the SEC industry classification Services-Commercial Physical & Biological Research.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CRL | INCY |
|---|---|---|
| Market Cap | $16.80B | $23.57B |
| P/E Ratio | – | 44.79x |
| P/B Ratio | 5.92x | 4.18x |
| EPS | $-4.00 | $2.68 |
| Book Value/Share | $59.48 | $28.74 |
| Revenue/Share | $83.77 | $30.62 |
| FCF/Share | $7.76 | – |
Profitability & Margins
| Metric | CRL | INCY |
|---|---|---|
| ROE | -8.4% | 7.2% |
| ROA | -3.2% | 5.5% |
| ROIC | 1.4% | 10.7% |
| Gross Margin | – | 92.7% |
| Operating Margin | 2.2% | 10.4% |
| Net Margin | -6.0% | 6.7% |
| EBT Margin | -0.9% | 13.2% |
| Tax Rate | -152.4% | 49.3% |
Financial Health
| Metric | CRL | INCY |
|---|---|---|
| Current Ratio | 1.35x | 3.84x |
| Quick Ratio | 1.04x | 3.75x |
| D/E Ratio | 1.64x | 0.29x |
| Financial Leverage | 2.65x | 1.29x |
| Interest Coverage | 5.0x | 213.7x |
| Working Capital | $394M | $4.08B |
Cash Flow
| Metric | CRL | INCY |
|---|---|---|
| Operating Cash Flow | $582M | $745M |
| Free Cash Flow | $371M | – |
| Capital Spending | -$212M | – |
| OCF Growth YoY | -26.1% | -40.5% |
| FCF Growth YoY | -35.9% | – |
| FCF/Sales | 9.3% | – |
| CapEx/Sales | 5.3% | – |
Operational Efficiency
| Metric | CRL | INCY |
|---|---|---|
| Asset Turnover | 0.53x | 0.82x |
| Receivables Turnover | 5.6x | 4.9x |
| Inventory Turnover | – | 3.3x |
| Fixed Assets Turnover | 2.7x | 8.6x |
| Days Sales Outstanding | 65 days | 75 days |
| Days Inventory | – | 112 days |
| Payables Period | – | 196 days |
| Cash Conversion Cycle | – | -9 days |
Income Statement
| Metric | CRL | INCY |
|---|---|---|
| Total Revenue | $4.00B | $6.01B |
| Operating Income | $90M | $627M |
| Net Income | -$238M | $403M |
| R&D Expense | – | $3.44B |
| SG&A Expense | $762M | $1.43B |
| Cost of Goods Sold | – | $439M |
Dividend & Shareholder Information
| Metric | CRL | INCY |
|---|---|---|
| Shares Outstanding | 48M | 196M |
| Net Income Growth | – | -66.1% |
| EPS Growth | – | -53.8% |
CRL vs INCY: stock comparison and AI forecast
Which is bigger, CRL or INCY?
INCY is 1.4 times larger than CRL by market capitalization ($23.57B against $16.80B).
Which one does Intratio's AI model rank higher, CRL or INCY?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.